

APR 28 2003

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application No.	09/865,879
Filing Date:	May 25, 2001
First Named Inventor	Roninson t al.
Group Art Unit	1642
Examiner Name	Misook Yu
Attorney Docket No.	99,216-H

Sheet	1	of	7
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
		Number	Kind Code ² (if known)			
my		5,444,164	A	PURCHIO ANTHONY et al.	08-22-1995	
↓		5,965,382	A	CASIPIIT CLAYTON et al.	10-12-1999	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
my		✓ WO	98/08546	A	Inst Nat Sante Rech Med	03-05-1998	RECEIVED MAY 01 2003 TECH CENTER 1600/2900	
		✓ WO	91/14695	A	Salk Inst for Biological Studi	10-03-1991		
		✓ WO	96/23080	A	Allergan Inc.	08-01-1996		
		✓ WO	01/18019	A	Chang David	03-15-2001		
		✓ WO	98/23747	A	Schering Corp.	06-04-1998		
		✓ WO	01/15520	A	Ortho McNeil Pharm Inc.	03-08-2001		
		✓ WO	98/31701	A	Univ. Texas	07-23-1998		
		✓ WO	00/09657	A	Lee Mu En; Harvard College	02-24-2000		
		✓ WO	00/29437	A	Berkenstam Anders; Pharmacia & Upjohn AB	05-25-2000		
		✓ WO	93/06835	A	DANA Farber Cancer Inst.	04-15-1993		
my		EP	0 280 135 A	A	Behringwerke AG	08-31-1988	Abstract only	

EP 0280135A only Abstract considered 9-1-03, my

Examiner Signature	Misook Yu	Date Considered	9-1-03
--------------------	-----------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

#4

RECEIVED
MAY 01 2003
TECH CENTER 1810/2900

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application No.	09/865,879
		Filing Date	May 25, 2001
		First Named Inventor	Roninson et al.
		Group Art Unit	1642
		Examiner Name	Misook Yu
Sheet	2	of	7
		Attorney Docket No.	99,216-H

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
my	✓	MING et al., "Expression genetics: a different approach to cancer diagnosis and prognosis", Trends in Biotechnology, Elsevier Publications, Cambridge, GB, vol. 16, no. 2, February 1, 1998, pages 66-71.	
	✓	HUANG et al. "Cloning and Characterization of a Novel Retinoid-Inducible Gene 1 (RIG1) Deriving from Human Gastric Cancer Cells" Molecular and Cellular Endocrinology, Amsterdam, Netherlands, vol. 159, no. 1/2, January 25, 2000, pages 15-24.	
	✓	KUMAR et al., "Setting up Reporter-Gene Based Assay Systems for Screening Antineoplastic Drugs", Pharmaceutical Technology, June 1, 1991, pages 39-43.	
	✓	DOKMANOVIC et al., "Molecular basis of senescence—like growth arrest induced in breast carcinoma cells by retinoids" Proceedings of the American Association for Cancer Research Annual., vol. 42, March 2001, page 210.	
	✓	DOKMANOVIC et al., "Retinoid-induced growth arrest of breast carcinoma cells involves co-activation of multiple growth-inhibitory genes" Cancer Biology & Therapy, 2002 Jan-Feb. vol. 1, no. 1, January 2002 pages 24-27.	
	✓	CUBBAGE et al., "Insulin-like Growth Factor Binding protein-3", Journal of Biological Chemistry, vol. 265, no. 21, July 15, 1990, 12642-12649.	
	✓	HEMBREE et al., "Retinoid X Receptor-Specific Retinoids Inhibit the Ability of Retinoic Acid Receptor-Specific Retinoids to Increase the Level of Insulin-Like Growth Factor Binding Protein-3 in Human Ectocervical Epithelial Cells", Cancer Research vol. 56, no. 8, April 15, 1996, pages 1794-1799.	
	✓	SHANG et al., "Signal relay by retinoic acid receptors alpha and beta in the retinoic acid-induced expression of insulin-like growth factor-binding protein-3 in breast cancer cells", Journal of Biological Chemistry, vol. 274, no. 25, June 18, 1999, pages 18005-18015.	
	✓	HAN et al., "All-trans-retinoic acid increases transforming growth factor-beta-2 and insulin-like growth factor binding protein-3 expression through a retinoic acid receptor-alpha-dependent signaling pathway", Journal of Biological Chemistry, vol. 272, no. 21, 1997, pages 13711-13716.	
	✓	SIMON et al., "Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase kinase, on urokinase expression and in vitro invasion", Cancer Research, vol. 56, no. 23, 1996, pages 5369-5374.	

Examiner Signature	<i>Misook Yu</i>	Date Considered	9-1-03
--------------------	------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

RECEIVED
MAY 01 2003

TECH CENTER 1600/2900

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application No.	09/865,879
Filing Date:	May 25, 2001
First Named Inventor	Roninson et al.
Group Art Unit	1642
Examiner Name	Misook Yu
Attorney Docket No.	99,216-H

Sheet 3 of 7


OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
my		✓ ALBISTON et al., "Cloning and characterization of the promoter for the rat insulin-like growth factor-binding protein-3 gene" Endocrinology, vol. 136, no. 2, 1995, pages 696-704.	
		✓ HELLER et al., "Transcriptional regulation of the Bmp2 gene. Retinoic acid induction in F9 embryonal carcinoma cells and Saccharomyces cerevisiae", Journal of Biological Chemistry, vol. 274, no. 3, January 15, 1999, pages 1394-1400.	
		✓ SKONIER et al., "CDNA Cloning and Sequence and Analysis of Beta-ig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-beta", DNA and Cell Biology, vol. 11, no. 7, 1992, pages 511-522.	
		✓ SKONIER et al., "Betaig-H3: A Transforming Growth Factor-Beta-Responsive Gene Encoding A Secreted Protein That Inhibits Cell Attachment in Vitro and Suppresses the Growth of Cho Cells in Nude Mice", DNA and Cell Biology, New York, NY, vol. 13, no. 6, 1994, pages 571-584. ✓	
		✓ TSUJIMOTO et al. "Differential gene expression in tumorigenic and nontumorigenic HeLa x normal human fibroblast hybrid cell", Molecular Carcinogenesis, vol. 26, no. 4, December 1999, pages 298-304.	
		✓ SCHENKER et al., "Down-regulated proteins of Mesenchymal tumor cells" Experimental Cell Research, vol. 239, no. 1, February 25, 1998, pages 161-168.	
		✓ DATABASE GenBank NCBI; 30 March 1998 AC004503.	
		✓ HU et al., "Profiling of differentially expressed cancer-related genes in esophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: overexpression of oncogene MET correlates with tumor differentiation in ESCC" Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, Nov. 2001, vol. 7, no. 11, November 2001, pages 3519-	
		✓ CHEN et al., "Characterization of the human EPLIN gene reveals distinct promoters for the two EPLIN isoforms" Gene vol. 248, no. 1-2, May 2, 2000, pages 69-76.	
		✓ MAUL et al., Eplin, Epithelial Protein Lost in Neoplasm" Oncogene, vol. 18, 1999, pages 7838-7841.	
		✓ YUAN-CHING et al., "A MHC-encoded ubiquitin-like protein (FAT10) binds noncovalently to the spindle assembly checkpoint protein MAD2" Proceedings of the National Academy of Sciences of the United States, vol. 96, no. 8, April 13, 1999, pages 4313-4318.	
Examiner Signature	[Signature]		Date Considered 9-1-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231



RECEIVED
MAY 01 2003
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application No.	09/865,879		
		Filing Date:	May 25, 2001		
		First Named Inventor	Roninson et al.		
		Group Art Unit	1642		
		Examiner Name	Misook Yu		
Sheet	4	of	7	Attorney Docket No.	99,216-H

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
my		✓ RAASI et al., "A ubiquitin-like protein which is synergistically inducible by interferon-gamma and tumor necrosis factor-alpha", European Journal of Immunology, Germany, Dec. 1999, vol. 29, no. 12, pages 4030-4036.	
		✓ DATABASE EMBL Online, October 27, 1998, Database Accession no. AL031983.	
		✓ RAASI et al., "The ubiquitin-like protein FAT10 forms covalent conjugates and induces apoptosis", Journal of Biological Chemistry, vol. 276, no. 38, September 21, 2001 pages 35334-35343.	
		✓ DATABASE EMBL Online, January 11, 2000, Database Accession no. AL136295.	
		✓ FRISAN et al., "Variations in proteasome subunit composition and enzymatic activity in B-lymphoma lines and normal B cells." International Journal of Cancer, vol. 88, no. 6, 2000, pages 881-888.	
		✓ GROETTRUP et al., "A role for the proteasome regulator PA28-alpha in antigen presentation.", Nature (London), vol. 381, no. 6578, 1996, pages 166-168.	
		✓ DELP et al, "Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin", Bone Marrow Transplantation, vol. 25, no. Supplement 2, May 2000, pages S88-S95.	
		✓ WOJCIK and WILK, "Changes in proteasome expression and activity during differentiation of neuronal precursor Ntera 2 clone D1 cells", Neurochemistry International, vol. 34, 1999, pages 131-136.	
		✓ RITZ et al., "Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma." International Journal of Oncology, vol. 19, no. 6, December 2001, pages 1211-1220.	
		✓ BRAKEBUSCH et al., "Isolation and functional Characterization of the Human 90K promoter." Genomics, vol. 57, no. 2, April 15, 1999, pages 268-278.	
		✓ CHANG et al., "Effects of p21WAF1/CIP1/SDI1 on Cellular Gene Expression: Implications for Carcinogenesis, Senescence, and Age-Related Diseases" Proceedings of the National Academy of Sciences of USA, National Academy of Science. Washington, US. Vol. 97, no. 8, April 2000, pages 4291-4296.	
Examiner Signature			Date Considered
			9-1-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231



RECEIVED
MAY 01 2003
TECH CENTER 1600/2900

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application No.	09/865,879		
		Filing Date:	May 25, 2001		
		First Named Inventor	Roninson et al.		
		Group Art Unit	1642		
		Examiner Name	Misook Yu		
Sheet	5	of	7	Attorney Docket No.	99,216-H

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
MY		✓ BRAKEBUSCH et al., "Expression of the 90K immunostimulator gene is controlled by a promoter with Unique Features" Journal of Biological Chemistry, vol. 272, no. 6, 1997 pages 3674-3682.	
		✓ MARCHETTI ANTONIO et al: "Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients." Cancer Research, May 1, 2002, vol. 62, no. 9, pages 2535-2539.	
		✓ HAYASHI et al., "Regulation of the human protein C inhibitor gene expression in HepG2 cells: role of Sp1 and AP2", The Biochemical Journal, June 1, 1998, vol. 332, June 1, 1998.	
		✓ SUZUKI et al. "Protein C inhibitor (PAI-3): Structure and multi-function." Fibrinolysis & Proteolysis, vol. 14, no. 2-3, March 2000, pages 133-145.	
		✓ DATABASE EMBL Online EBI; November 15, 1999, Accession No. AL132990.	
		✓ HETTMANN et al., "The Human T Cell Receptor Gamma Genes are Transcribed from Tata-less Promoters Containing a Conserved Heptamer Sequence", Molecular Immunology, vol. 29, no. 9, 1992, pages 1073-1080.	
		✓ DATABASE EMBL 'Online' November 23, 1989 Accession No. X15274.	
		✓ ESSAND et al., "High expression of a specific T-cell receptor gamma transcript in epithelial cells of the prostate", Proceedings of the National Academy of Science, vol. 96, August 1999, pages 9287-9292.	
		✓ WRIGHT et al., "Molecular Cloning, refined chromosomal mapping and structural analysis of the human gene encoding aldehyde oxidase (AOX1), a candidate for the ALS2 gene", Redox Report, vol. 3, 1997, pages 135-144.	

Examiner Signature		Date Considered	9-1-03
-----------------------	--	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

#14

RECEIVED

MAY 01 2003

Substitute for form 1449A/PTO

TECH CENTER 1600/2900

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application No.	09/865,879
Filing Date:	May 25, 2001
First Named Inventor	Roninson et al.
Group Art Unit	1642
Examiner Name	Misook Yu
Attorney Docket No.	99,216-H

Sheet 6 of 7

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
Amj		✓ TERAQ et al., "Isolation and characterization of the human aldehyde oxidase gene: conservation of intron/exon boundaries with the xanthine oxidoreductase gene indicates a common origin", The Biochemical Journal, England, June 1, 1998, vol. 332.	
		✓ TOMITA et al., "Retinal oxidase is identical to aldehyde oxidase", FEBS Letters, vol. 336, no. 2, 1993, pages 272-274.	
		✓ SATO et al., "Changes of gene expression by lysophosphatidylcholine in vascular endothelial cells: 12 Up-regulated distinct genes including 5 cell growth-related, 3 thrombosis-related, and 4 others.", Journal of Biochemistry, vol. 123, no. 6, June 1998, pages 1119-1126.	
		✓ LAUTNER-RIESKE et al., "Searching for non-Vkappa transcripts from the human immunoglobulin kappa locus", Gene, Elsevier Biomedical Press., Amsterdam, NL. Vol. 159, no. 2, July 4 1995, pages 199-202.	
		✓ DATABASE Genbank, Shimizu and Kawasaki, "Homo sapiens genomic DNA, chromosome 2p11.2, clone:cos607/4", Accession no. AP001234.	
		✓ DEL CARMEN DE MARCO MARIA et al. "Bene, a novel raft-associated protein of the MAL proteolipid family, interacts with caveolin-1 in human endothelial-like ECV304 cells" Journal of Biological Chemistry, vol. 276, no. 25, June 22, 2001, pages 23009-23017.	
		✓ WIESENER et al., "Induction of endothelial PAS domain protein-1 by hypoxia: Characterization and comparison with hypoxia-inducible factor-alpha", Blood, vol. 92, no. 7, October 1, 1998, pages 2260-2268.	
		✓ DATABASE EMBL "Online" December 14, 1999, Sulston: "Homo sapiens BAC clone RP11-130P22 form 2, complete sequence", Accession No. AC016696.	
		✓ DANG et al., "Oncogenes in Tumor Metabolism, Tumorigenesis, and Apoptosis", Journal of Bioenergetics and Biomembranes, plenum publishing, New York, NY, US, vol. 29, no. 4, August 1997, pages 345-354.	

Examiner Signature	Misook Yu	Date Considered	9-1-03
--------------------	-----------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

<div style="text-align: center;">  <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p> </div>		Complete if Known	
		Application No.	09/865,879
		Filing Date :	May 25, 2001
		First Named Inventor	Roninson et al.
		Group Art Unit	1642
		Examiner Name	Misook Yu
Sheet 7 of 7	Attorney Docket No.	99,216-H	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
MS	✓	FELDSER et al., "Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2", Cancer Research, American Association for Cancer Research, vol. 59, August 15, 1999, pages 3915-3918.	
	✓	BLANCHER et al., "The Molecular Basis of the Hypoxia response Pathway: Tumour hypoxias a therapy target", Cancer Metastasis, vol. 17, 1998, pages 187-194.	
	✓	TALKS et al., "The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages." American Journal of Pathology, August 2000, vol. 157, no. 2, August 2000, pages 411-421.	
	✓	ORD et al., "Structure of the Gene Encoding the Human Leukocyte Adhesion Molecule-1 TQ1 LEU-8 of Lymphocytes and Neutrophils", Journal of Biological Chemistry, vol. 265, no. 14, 1990, pages 7760-7767.	
	✓	DATABASE Biosis "Online" Biosciences Information Service, Philadelphia, PA, February 2000, Accession no. PREV200000177491 XP002224066.	
	✓	TATEWAKI et al., "Constitutive overexpression of the L-selectin gene in fresh leukemic cells of adult T-cell leukemia that can be transactivated by human T-cell lymphotropic virus type 1 Tax." Blood, United States, October 15, 1995, pages 3109-3117.	
	✓	QIAN et al., "L-selectin can facilitate metastasis to lymph nodes in a transgenic mouse model of carcinogenesis." Proceedings of the National Academy of Sciences of the United States, vol. 98, no. 7, March 27, 2001, pages 3976-3981.	

Examiner Signature		Date Considered	9-1-03
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231